November 15, 2013—Drug-pricing provisions reportedly being advanced by U.S. negotiators for a proposed multilateral trade treaty could subject 340B drug discounts “to challenge by manufacturers,” a coalition of health, consumer, labor, and retiree groups says in a recent letter to President Obama.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)